Cycloalkyl alkanoic acids as integrin receptor antagonists derivatives
申请人:——
公开号:US20040092538A1
公开(公告)日:2004-05-13
The present invention relates to a class of compounds represented by the Formula I
1
or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising compounds of the Formula I, and methods of selectively inhibiting or antagonizing the &agr;
v
&bgr;
3
and/or &agr;
v
&bgr;
5
integrin.
本发明涉及一类由公式I代表的化合物
1
或其药用可接受的盐,包含公式I化合物的药物组合物,以及选择性地抑制或拮抗α
v
β
3
和/或α
v
β
5
整合素的方法。
[EN] GPR120 RECEPTOR AGONISTS AND USES THEREOF<br/>[FR] AGONISTES DU RÉCEPTEUR GPR120 ET LEURS UTILISATIONS
申请人:METABOLEX INC
公开号:WO2011159297A1
公开(公告)日:2011-12-22
GPR120 agonists are provided. These compounds are useful for the treatment of metabolic diseases, including Type II diabetes and diseases associated with poor glycemic control.
[EN] GPR120 RECEPTOR AGONISTS AND USES THEREOF<br/>[FR] AGONISTES DE RÉCEPTEURS GPR 120 ET LEURS APPLICATIONS
申请人:METABOLEX INC
公开号:WO2010080537A1
公开(公告)日:2010-07-15
GPR120 agonists are provided. These compounds are useful for the treatment of metabolic diseases, including Type II diabetes and diseases associated with poor glycemic control.
Electrochemical carboxylation of benzylic carbonates was successfully performed as an alternative method for the synthesis of phenylacetic acids by using a one-compartment cell equipped with a Pt plate cathode and an Mg rod anode in CH3CN to afford the corresponding phenylacetic acids in good yields.
GPR120 agonists are provided. These compounds are useful for the treatment of metabolic diseases, including Type II diabetes and diseases associated with poor glycemic control.